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Young children are susceptible to enterovirus (EV) infections, which cause significant mor-
bidity in this age group. However, the current knowledge regarding the epidemiology of EVs
and the circulating virus strains is mostly based on viruses detected in children with severe
diseases leading to contact with the health care system, while the vast reservoir of EVs that
circulate in the general population is less characterized.
Methodology
The present study investigates the types and the prevalence of EVs circulating in the young
children of the background population in Georgia, Colorado, and Washington State in the
USA, and Germany, Sweden, and Finland in Europe.
A total of 4018 stool samples, collected monthly from 300 healthy and non-hospitalized
children at the age of 3–18 months in 2005–2009, were analyzed for the presence of EVs
using RT-PCR, followed by sequencing of the VP1-2A region of the viral genome to type the
EV(s) present. All of the children carried type HLA-DQ2 or -DQ8 alleles associated with type
1 diabetes.
Principal findings
Altogether 201 children (67%) were found to be EV positive. The prevalence was much
lower in Finnish children (26%) than in the children of the other counties combined (75%).
Infections increased by age and showed a nadir during the winter months. Children who car-
ried both the HLA-DQ2 and -DQ8 alleles had less infections than children who were homo-
zygous for these alleles. Coxsackieviruses type A were the most frequently detected
viruses in all geographical regions. Coxsackievirus type A4, Echovirus type 18, and Echovi-
rus type 25 were shed for longer time periods than the other EV types.
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Conclusions
Compared to prevalence data from symptomatic patients requiring medical attention, this
study provides a better view of EVs circulating in young children in the USA and in Europe.
The observations may prove useful for the selection of strategies for designing EV vaccines
in the future. The study also confirms our previous serological findings suggesting that EV
infections are relatively rare in Finland.
1. Background
Enteroviruses (EVs) are among the most common human viruses infecting nearly one billion
people annually worldwide [1]. Even though most EV infections are asymptomatic or mild,
EVs are responsible for a vast number of severe infections every year, including paralysis,
encephalitis, aseptic meningitis, pleurodynia, pericarditis, myocarditis, hand-foot-and-mouth
disease (HFMD), herpangina, severe neonatal systemic disease, and acute haemorrhagic con-
junctivitis [2]. Young infants are susceptible to severe EV diseases, possibly due to their imma-
ture immune system.
EVs belong to the family Picornaviridae consisting of 15 species including Enterovirus A-L,
and Rhinovirus A-C [3]. The EV species A, B, C and D infect humans, and they are tradition-
ally divided into Poliovirus (PV) consisting of three serotypes, Coxsackievirus type A (CV-A)
with 23 serotypes, Coxsackievirus type B (CV-B) with 6 serotypes, and Echovirus (E) consist-
ing of 28 serotypes [4], as well as some more recently discovered numbered serotypes.
EVs show both endemic and epidemic patterns [5]. Epidemics are typically caused by cer-
tain EV types such as E-30 (causing aseptic meningitis), EV-D70 (causing acute hemorrhagic
conjunctivitis), EV-A71 (causing severe central nervous system disease in the Far East),
CV-A6 and CV-A10 (causing severe HFMD), and EV-D68 (causing flu-like symptoms) [1,6].
Recent advances in the molecular typing of EVs by sequencing have greatly improved our
ability to study their epidemiology. These methods have also enabled the identification of EVs
that are difficult to propagate in cell culture [7–9], and the accurate typing and classification
based on genomic sequences [10–12]. A method introduced by Nix et al. [13] has been widely
used for molecular typing of EVs. It uses a consensus degenerate hybrid oligonucleotide
primer (CODEHOP) approach and amplifies VP1 coding region of all known EV serotypes
[14].
Although these methods have advanced epidemiological studies in hospitalized patients,
very little is still known about the epidemiology of EVs in the general population, where EV
infections remain mainly asymptomatic or mild. These “hidden/subclinical” infections can
have important health consequences, since they constitute a reservoir of EVs, which varies
constantly due to recombination and a high mutation rate, thus leading to outbreaks and
severe diseases in susceptible populations. In addition, some of these viruses may play a role in
chronic diseases, such as type 1 diabetes (T1D) and cardiomyopathies, even if they do not
cause any other apparent symptom [15,16].
2. Objective
The aim of this study was to characterize the large reservoir of EVs that circulate in young chil-
dren in the general population of different geographical regions.
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3. Materials and methods
3.1. Study population and collection of stool samples
The study subjects were selected randomly from the children who participated in a large birth-
cohort study named “The Environmental Determinants of Diabetes in the Young (TEDDY)”
recruiting children in six study centers in the USA and Europe. In the TEDDY study, large
numbers of samples including blood and stool specimens are collected from children with
genetically increased risk of T1D (19). Participants of the present study represent a randomly
selected sub-cohort of TEDDY not enriched for any disease, sex or ethnic group. The partici-
pants were recruited from the general population and had no first-degree relatives with T1D.
Study subjects carried one of the T1D-associated HLA-DQ genotypes that were screened for at
birth (for further information see Hagopian et al. [17]). At the time of selection, all participants
were non-diabetic and negative for T1D-associated autoantibodies.
A total of 4018 stool samples were collected monthly between the 17th of January 2005 and
the 16th of March 2009 from 300 children including 147 girls and 153 boys aged 3-18 months, of
whom 10 became positive for T1D autoantibodies and one child was eventually diagnosed with
T1D (by the end of September 2016). The HLA-DQ genotypes were DQ2/8 (50% of the partici-
pants), DQ2/2 (27%) and DQ8/8 (23%). The distribution of the HLA types; however, differed
across the study centers (S1 Table). It is worth mentioning that other HLA types, which pose an
increased risk for T1D, were not included in this study. Altogether 20 (6.7%) children belonged to
an ethnic minority (Hispanic, African American or other ethnic minority in the USA).
The sample series included 662 stool samples from 51 children in Colorado (COL), 669
samples from 50 children in Georgia (GEO), 668 samples from 50 children in Washington
(WAS), 702 samples from 50 children in Finland (FIN), 645 samples from 49 children in Ger-
many (GER), and 672 samples from 50 children in Sweden (SWE) as shown in Table 1.
A median number of 13 samples were collected per child (range 2-16), and 99% of the chil-
dren were sampled 8–16 times during the study period. Samples were collected evenly
throughout the year in all centers (S2 Table) and their number did not differ significantly
between the study sites (Table 1). Samples were collected at home by the parents and were sent
Table 1. Number of stool samples and children studied, and EV positivity rates in different study centers.







COL 662 106 (16) 88 (83) 51 31 (61)
GEO 669 160 (24) 136 (85) 50 46 (92)
WAS 668 97 (15) 75 (77) 50 34 (68)
Sub total 1999 368 (18) 299 (81) 151 111 (74)
FIN 702 23 (3) 9 (39) 50 13 (26)
GER 645 93 (14) 79 (85) 49 36 (73)
SWE 672 107 (16) 92 (86) 50 41 (82)
Sub total 2019 225 (11) 180 (80) 149 90 (60)
Total 4018 586 (15) 479 (82) 300 201 (67)
 Percent of the samples
 Percent of EV positives, which are typed
 Percent of the children positive for EV
The number of samples and the percentage where the type of EV was identified by sequencing are also shown. Study centers include Colorado (COL), Georgia (GEO),
Washington (WAS), Finland (FIN), Germany (GER), and Sweden (SWE).
https://doi.org/10.1371/journal.pone.0201959.t001
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to the TEDDY repository using express courier mail in the USA, or to local TEDDY centers in
Europe using regular local mail. They were kept at an ambient temperature for one to three
days during the shipment and temperature peaks during shipment were prevented by an ice-
gel pack. Samples were stored at -80˚C on arrival at the first destination.
Data on clinical symptoms were collected by parents at home using a diary and were trans-
lated to different symptom and disease codes (ICD-10 codes) by study nurses at each study
visit. The details of the procedures used for the collection of symptom data have been
described previously [18].
3.2. Ethics statement
The TEDDY study was approved by local U.S. Institutional Review Boards and European Eth-
ics Committee Boards in Colorado’s Colorado Multiple Institutional Review Board, Georgia’s
Medical College of Georgia Human Assurance Committee (2004–2010), Georgia Health Sci-
ences University Human Assurance Committee (2011–2012), Georgia Regents University
Institutional Review Board (2013–2015), Augusta University Institutional Review Board
(2015-present), Florida’s University of Florida Health Center Institutional Review Board,
Washington state’s Washington State Institutional Review Board (2004–2012) and Western
Institutional Review Board (2013-present), Finland’s Ethics Committee of the Hospital District
of Southwest Finland, Germany’s Bayerischen Landesa¨rztekammer (Bavarian Medical Associ-
ation) Ethics Committee, Sweden’s Regional Ethics Board in Lund, Section 2 (2004–2012) and
Lund University Committee for Continuing Ethical Review (2013-present).
3.3. Enterovirus detection and typing
Stool suspensions (10% w/v) were prepared by thawing the samples and diluting them in
Hanks balanced salt solution (HBSS, Sigma) containing 4% fetal calf serum (FCS). Suspensions
were clarified by centrifugation at 500xg for 20 minutes at 4˚C. Clarified supernatants were
collected in aliquots in sterile cryo-preservation tubes and were stored at -80˚C. EV RNA was
extracted using a high-throughput nucleic acid extraction method (MagNa Pure extraction
robot, Roche, Applied Science, Germany—using Total Nucleic Acid extraction kit, Roche).
The viral genome was then detected by real-time RT-PCR as described elsewhere [19] using
primers and probes shown in S3 Table. An average cycle threshold (Ct) from triplicate sample
wells was used with a cut-off of 46 for positivity. All positive samples were further investigated
by partial sequencing of a stretch of the VP1 coding region as described by Nix et al. [13].
In our study approximately 350-400 nucleotides were identified by sequencing, depending
on the virus type. To identify the EV genotype, sequences were analyzed using “Enterovirus
Genotyping Tool Version 0.1”; an online tool developed by the National Institute for public
Health and Environment (RIVM), Bilthoven, the Netherlands [20].
3.4. Statistical analyses
The SPSS statistical package (version 22) was used for the analyses. The Kruskal-Wallis or
Mann-Whitney U test was used to identify the statistical significance of the differences
between groups. The Z-test was used to compare two proportions expressed as percentages.
Binary logistic regression was used to analyze the probability of being EV positive according to
the HLA-type, study center and sex of the child. The statistical significance was set to p = 0.05.
The prevalence of infections was defined as the proportion of children with at least one EV
positive stool sample (child positivity rate). The rate of sample positivity was defined as the
proportion of EV positive samples. Infection episodes were defined by the detection of a soli-
tary EV positive sample or the detection of the same EV strain in consecutive samples
Enterovirus molecular epidemiology in young children
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(identified by identical sequences). If the sequencing failed, Ct-values were used to identify the
episode. An increase in the Ct-values in consecutively positive samples was assumed to repre-
sent one episode (indicating a decline in the virus shedding). An algorithm was created to cal-
culate the length of an infection episode (S1 Fig).
4. Results
4.1. Prevalence of enterovirus infections
Altogether 14.6% of all samples were EV positive by real-time RT-PCR using a cut-off of
Ct = 46 (the majority of them were still EV positive using a lower cut-off of Ct = 42 being posi-
tive in 14.1% of total samples, S2 Fig). Sample positivity rate was the lowest in Finland (3.3%)
and the highest in Georgia (24%, Fig 1). The mean Ct-value of positive samples (N = 586) was
31.5 (range 15.7–45.6, SD 6.8) showing no difference between the centers (p = 0.54).
Fig 1. Prevalence of EVs represented as the child positivity rate and sample positivity rate in each study center. The difference in positivity rates between Finland
and all other study centers is statistically significant in each category (p<0.001). Study centers include Georgia (GEO), Washington (WAS), Colorado (COL), Finland
(FIN), Sweden (SWE) and Germany (GER).
https://doi.org/10.1371/journal.pone.0201959.g001
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At least one EV positive stool sample was detected in 67% of the study participants. The
proportion of EV positive children was much lower in Finland than in the other countries
combined (26% vs. 75%, p<0.001; Fig 1). The highest rates were seen in Georgia, where 92%
of the children were EV positive. The prevalence of EV infections increased with the age of the
child (S3 Fig). The mean number of positive samples per child was 1.98 (SD 2.05, Median of 1,
interquartiles of 0, 1, and 3).
A clear seasonal pattern was seen in all geographical regions showing a peak during spring,
summer, and autumn months (March-October) with some variation between the study centers
(Fig 2). Sample positivity rate peaked in certain years. Colorado had a significantly higher
number of EVs in 2007 (25%) compared to the average of 9.5% for other years (p<0.001).
Georgia had a significantly higher number of EVs in 2008 (30%) compared to 21% for all other
years (p = 0.018).
4.2. Prevalence of different enterovirus types
Typing was successful in 82% of the EV-positive samples (479 samples; Table 1). The success
rate of genotyping depended on the virus load, since the typed samples had significantly lower
average Ct-values compared to un-typed samples (mean Ct-value 30 versus 37, p<0.001). The
majority (61.5%) of the genotyped viruses belonged to the species Enterovirus A (EV-A), 38%
to Enterovirus B (EV-B) and only 0.5% to Enterovirus C (EV-C) (Table 2). Interestingly some
human rhinoviruses (HRVs) were also amplified by the sequencing primers, because of their
sequence homology with EVs (six samples); these were excluded from the analysis.
Fig 2. Seasonal distribution of EV-positive stool samples in different study centers. The year has been devided into 4 seasons from March to February (Spring
includes March, April and May). The total number of EV-positive samples in each season is shown for each study center.
https://doi.org/10.1371/journal.pone.0201959.g002
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CV-As were the most frequently detected EVs in all study centers. 37.7% of all children
experienced at least one CV-A infection and 61.7% of all genotyped EVs were CV-As
(Table 2). The second most common viruses were echoviruses (Es) that were detected in
16.3% of the children and 19% of the genotyped samples, followed by CV-Bs that were
detected in 14.7% of the children and 16.1% of the genotyped samples (Table 2). Of the indi-
vidual EVs CV-A4 was the most common virus in the stool samples (18.2% of all typed EVs)
followed by CV-A6 (11.9%), CV-A2 (9.6%), CV-A5 (7.8%), and CV-A10 (5.7%; Table 2), a pat-
tern which showed only minor variations between different centers. Only 3.1% of all typed
Table 2. Type of EVs in each study center and the rank of the virus among all typed viruses.
Number of typed viruses in stool samples (Ranks) % of
typed virusesSpecies Genotype USA COL GEO WAS Europe FIN GER SWE Total
EV-A CV-A2 31 (2) 9 (2) 17 (1) 5 (4) 6 (7) 1 (2) 3 (5) 2 (8) 37 (3) 9.6
CV-A4 48 (1) 22 (1) 12 (2) 14 (1) 22 (1) 3 (1) 9 (1) 10 (1) 70 (1) 18.2
CV-A5 18 (4) 2 (6) 5 (7) 11 (3) 12 (3) 0 5 (3) 7 (3) 30 (4) 7.8
CV-A6 29 (3) 6 (3) 11 (3) 12 (2) 17 (2) 1 (2) 7 (2) 9 (2) 46 (2) 11.9
CV-A8 2 (13) 0 2 (10) 0 2 (11) 0 1 (7) 1 (9) 4 (15) 1.0
CV-A10 12 (5) 1 (7) 7 (5) 4 (5) 10 (4) 0 5 (3) 5 (5) 22 (5) 5.7
CV-A16 10 (7) 2 (6) 6 (6) 2 (7) 5 (8) 0 1 (7) 4 (6) 15 (7) 3.9
EV-A71 3 (12) 0 2 (10) 1 (8) 9 (5) 0 3 (5) 6 (4) 12 (10) 3.1
Sub total 153 42 62 49 83 5 34 44 236 61.5
EV-B CV-A9 5 (10) 0 5 (7) 0 6 (7) 0 2 (6) 4 (6) 11 (11) 2.9
CV-B1 12 (5) 5 (4) 3 (9) 4 (5) 2 (11) 0 2 (6) 0 14 (8) 3.6
CV-B2 8 (8) 1 (8) 6 (6) 1 (8) 2 (11) 0 0 2 (8) 10 (12) 2.6
CV-B3 5 (10) 2 (6) 2 (10) 1 (8) 8 (6) 0 5 (3) 3 (7) 13 (9) 3.4
CV-B4 8 (8) 4 (5) 3 (10) 1 (8) 8 (6) 0 7 (2) 1 (9) 16 (6) 4.2
CV-B5 4 (11) 0 4 (8) 0 5 (8) 0 0 5 (5) 9 (13) 2.3
E-3 4 (11) 0 4 (8) 0 0 0 0 0 4 (15) 1.0
E-6 6 (9) 0 4 (8) 2 (7) 4 (9) 0 1 (7) 3 (7) 10 (12) 2.6
E-9 1 (14) 0 0 1 (8) 3 (10) 0 2 (6) 1 (9) 4 (15) 1.0
E-11 4 (11) 2 (6) 1 (11) 1 (8) 9 (5) 0 5 (3) 4 (6) 13 (9) 3.4
E-13 2 (13) 0 2 (11) 0 6 (7) 0 4 (4) 2 (8) 8(14) 2.1
E-18 11 (6) 5 (4) 3 (9) 3 (6) 1 (12) 0 1 (7) 0 12 (10) 3.1
E-21 0 0 0 0 1 (12) 0 0 1 (9) 1 (16) 0.3
E-25 12 (5) 2 (6) 9 (4) 1 (8) 1 (12) 0 0 1 (9) 13 (9) 3.4
E-30 5 (10) 0 4 (8) 1 (8) 3 0 2 (6) 1 (9) 8 (14) 2.1
Sub total 87 21 50 16 59 0 31 28 146 38
EV-C CV-A1 0 0 0 0 1 (12) 0 0 1 (9) 1 (16) 0.3
CV-A22 1 (14) 0 1 (11) 0 0 0 0 0 1 (16) 0.3
Sub total 1 0 1 0 1 0 0 1 2 0.5
Total 241 63 113 65 143 5 65 73 384 100
Number of typed group of viruses in stool samples (%)
All CVA 156 (64.7) 42 (66.7) 66 (58.4) 48 (73.8) 81 (56.6) 5 (100) 33 (50.8) 43 (58.9) 237 (61.7) -
All CVB 37 (15.4) 12 (19) 18 (15.9) 7 (10.8) 25 (17.5) 0 14 (21.5) 11 (15.1) 62 (16.1) -
All EVs 45 (18.7) 9 (14.3) 27 (23.9) 9 (13.8) 28 (19.6) 0 15 (23.1) 13 (17.8) 73 (19) -
Typed viruses are categorized in species EV-A, EV-B, and EV-C. Each child can be positive for a number of EVs. The number of each virus type is shown for each study
center. The data from the USA, Europe, and the total numbers are shown separately for comparison. The last column shows the percentage of each virus (and species)
among all typed viruses. Numbers in the brackets represent the rank of the virus among all viruses in each category (column). At the bottom 3 rows of the table the total
number (and the percentage) of CVA, CVB, and EVs are presented.
https://doi.org/10.1371/journal.pone.0201959.t002
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EVs were EV-A71 and no EV-D68 was found. However, due to it’s biological properties,
EV-D68 is hard to detect in stool samples. Among different study centers, Germany had the
most frequent CVBs (22% of the samples), followed by Colorado (19%), Georgia (16%), Swe-
den (15%), and Washington (11%) (Table 2).
EVs were detected rarely before the age of 6 months becoming more frequent at older age
(S6 Table) and certain CAVs (CVA2, 4, 5, 6) showed an epidemic pattern peaking in certain
years (S6 Table).
None of the children in this study had meningitis, myocarditis, encephalitis, paralysis or
other severe symptoms typical for EV infection. Only 1/95 children with EV-A infection had
symptoms compatible with HFMD (commonly caused by CV-A6, A10, A16 or EV-A71) at the
time of the infection episode; the child was positive for CV-A6.
Duration of virus shedding. A total number of 411 EV episodes were identified using the
criteria described in S1 Fig, of these 315 had a positive identification of the virus genotype.
Altogether 268 (65.5%) of the episodes included only a single EV positive sample, 112 (27.3%)
had two, 25 (6.1%) three, and 6 (1.5%) had four consecutive positive stool samples. At least
one infection episode was observed in 164 children (55% of total participants) and 71 (43%) of
them had only one infection episode, 51 (31%) had two episodes, 28 (17%) had three episodes,
12 (7%) had four episodes (7.3%), and 2 (1%) had five episodes. Finnish children had signifi-
cantly less episodes than children in other countries (p<0.001, Fig 3). The mean duration of
the infection episodes was 38 days (SD 20.4 days, median 30 days, interquartiles 24, 30, and
50) showing no difference between the study centres (p = 0.08, Fig 3).
Among the successfully genotyped EV episodes CV-A4 episodes (N = 52) were character-
ized by significantly longer virus shedding time compared to all other EV types (mean 51 vs.
36 days, p<0.01; Fig 4). Similarly, E-18 episodes (N = 9) were longer compared to all other
EVs (mean 59 vs. 36, p = 0.026), and the same was true for E-25 (N = 9; mean 47 vs. 38 days,
p = 0.026; Fig 4). On the other hand, the episodes caused by un-typed EVs were significantly
Fig 3. The number of EV infection episodes (A) and the duration of episodes (B) in different study centers. The number of infection episodes is shown by the
number of the subjects having 0, 1, 2, or more than 2 infection episodes per child (A) and the duration of the episodes is shown in days (B). The thick horizontal lines in
the boxes represent the median for each center with the inter-quartile values; the circles represent the outliers (B).
https://doi.org/10.1371/journal.pone.0201959.g003
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shorter compared to the episodes caused by typed EVs (mean 28 vs. 41 days, p<0.001). This
may be a result of timing of sample collection (recovery phase of the infection) or the low levels
of the virus shed in the un-typed episodes. Corresponding frequencies of EV episodes caused
by different EV genotypes are shown in S4 Table.
4.3. Effect of host factors on enterovirus infections
65.3% of girls and 67.3% of boys were infected at least once with EVs (p = 0.54). The duration
of the infection episodes did not differ between them either. However, the HLA genotype cor-
related with EV positivity, as children who were HLA-DQ2/8 heterozygous were less fre-
quently EV positive compared to children who were homozygous for either HLA-DQ2 or
HLA-DQ8 (P = 0.048; Fig 5 and S4 Fig).
5. Discussion
To our knowledge, this may be the largest study carried out so far to characterize EVs in other-
wise healthy, young children in different countries, by analyzing stool samples which had
been collected on a monthly basis and examined for the presence of EV RNA, followed by
sequencing of an RT-PCR-amplified region of viral genome to identify the type of these EVs.
Fig 4. Duration of EV infection episodes caused by different EV serotypes compared to all other episodes. The duration of CV-A4 infection episodes was
significantly longer compared to all other enterovirus types together (p<0.001). E-18 and E-25 also had longer episodes (p = 0.026 and ^p = 0.026). The three viruses
together (CV-A4, E-18, and 25) had significantly longer infection episodes compared to the rest of the viruses (^^p<0.001). The length of infection episodes by un-typed
enteroviruses was significantly shorter compared to typed viruses (“p<0.001). All 3a refers to CV-A4, E-18 and E-25 together.
https://doi.org/10.1371/journal.pone.0201959.g004
Enterovirus molecular epidemiology in young children
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The results clearly demonstrate the abundance of species A EVs in these children, a finding that is
in contrast with the higher abundance of species B EVs reported in children with symptomatic
and severe infections. For example, the Centers of Disease Control (CDC) reports that 85% of the
Fig 5. Forest plots showing the prediction of EV positivity by HLA-DQ, sex, and study center. A forest plot representation of the odds ratios with
95% confidence intervals in a model of predicting EV positivity by HLA-DQ homozygosity, sex, and study center is shown here. Heterozygosity,
female sex, and Georgia were set as the reference groups, therefore they are missing from the graph.
https://doi.org/10.1371/journal.pone.0201959.g005
Enterovirus molecular epidemiology in young children
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top 15 prevalent strains of EVs belong to species B (see S5 Table) [21,22]. In addition, the present
study points out the comparatively low frequency of all EV infections in Finland.
One important strength of our study is that the study subjects were not selected on the basis
of symptoms or diseases. Thus, it provides information about the EVs circulating in young
children of the general population, regardless of the symptoms and is only biased by the selec-
tion of certain HLA types. When combined with the data from hospitalized patients, this infor-
mation will help to identify EVs with a high attack rate which are likely to cause clinically
significant diseases (see S5 Table). For example, based on the CDC reports by The National
Enterovirus Surveillance System (NESS) [23] CV-B group viruses (CV-B1 to 5) were detected
in 34.2% (477/1394) of all reported EVs during the same years as our study was conducted
(2006–2009) [1,21,22], while CV-Bs caused only 16.1% (N = 62) of EV infections diagnosed in
the present study, being detected in 14.7% (N = 44) of the children. In contrast to the present
study, reports by NESS are based on infections diagnosed through symptomatic disease volun-
tarily reported by participating laboratories since 1960s in the USA [23]. On the other hand,
many of the EV-A types that were frequent in the present study (e.g. CV-A2, A4 and A5) are
comparatively rare in hospitalized cases [1]. Comparison of our data to the reported NESS/
CDC data was hampered by the infrequency of EV-A in the symptomatic patients. EV-A71
and CV-A16 are mostly reported as the causative agents of HFMD [24–27]. We identified 15
children with CV-A16 and 12 children with EV-A71 ranking 7th and 10th of all detected EVs,
respectively. Interestingly, EV-D68 was not detected in any of our samples, despite its wide-
spread circulation in the USA in 2014 [28]. However, one should be aware of factors, which
may bias these comparisons. For example, CDC reports are based on varying virus detection
methods and samples that have been collected from various anatomical sites and age groups.
For example, the lack of respiratory samples may have led to an underestimation of the num-
ber of EVs that replicate predominantly in the respiratory track, including EV-D68 that was
completely absent in the present study. In addition, since sample were collected regularly with-
out extra samples taken when the child had symptoms of acute illness, the study probably
underestimates the true frequency of EVs, and this makes it difficult to accurately assess the
length of the infection episodes.
The observed abundance of the species A EVs is in line with previous studies carried out in
similar child cohorts in Sweden and Finland [19,29]. Similarly, a German study (Babydiet)
reported a surplus of EV-A compared to EV-B in healthy children with the highest prevalence of
CV-A4, CV-A2, CV-A10 and E-25 [30] which also ranked 1st, 3rd, 5th, and 9th in our study.
However, another study in Norway (MIDIA study) found EV-B types more frequently compared
to EV-A types [31]. Altogether, these results suggest that species A EVs may be responsible for the
majority of subclinical EV infections in children in Europe and in the USA. The five most fre-
quently detected EV types were CV-A2, A4, A5, A6 and A10, representing altogether 53% of all
identified EV infections. However, it is possible that the abundancy of different EV types may
vary over time and may differ with the sample type analyzed (e.g. respiratory vs. fecal samples).
One additional strength of this study is that the samples were directly analyzed by highly
sensitive RT-PCR without prior enrichment in cell cultures. This eliminated a possible under-
representation of the EV types that do not replicate well in cell culture [7–9]. On the other
hand, a potential weakness of the study was that the relatively low number of many of the indi-
vidual serotypes reduced the statistical power for comparing their occurrence in different pop-
ulations. In addition, more studies from other geographical regions are needed to obtain a
better understanding of global EV circulation patterns. Further studies are also needed to eval-
uate the circulation of EVs in older age groups and during longer time periods.
Some viruses, including CV-A4, E-18, and E-25 had a longer shedding time than other
EVs. This could be due to a less effective immunological response that fails to efficiently clear
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the infection or to other factors such as their strong tropism to the intestinal mucosa, higher
replication efficiency, or other intrinsic viral factors. The shedding of EVs into stools can vary
a lot and the longest reported shedding periods in immunocompetent children have ranged
6–11 weeks [32,33]. It was also reported that oral poliovirus type 3 vaccine strain can shed for
as long as 100 days in individual vaccinees (34).
The low prevalence of EV infections in Finland is in line with our previous serological stud-
ies [34,35]. The reason for this phenomenon is not known but, hypothetically, it could be
partly due to the cold climate—EVs circulate at low levels during the long winter season with
subfreezing temperatures. This is supported by the seasonal pattern that is typical for EV infec-
tions [36]. A low prevalence of EV infections may also make young children more susceptible
to a severe course of infection as previously described for poliovirus: The incidence of polio
paralysis started to increase at the end of the 19th century in western countries at the same time
when the circulation of the three poliovirus types decreased. This change was related to a shift
in the occurrence of the first infection to an older age, when maternal antibodies were no lon-
ger present in the children making them susceptible to the systemic spread of the virus and
subsequent clinical symptoms [37,38]. Analogously, it has been speculated that the limited cir-
culation of EVs could render Finnish children susceptible to EV infections and their spread to
the pancreas, and thereby contribute to the high incidence of T1D in Finland [39].
Host factors modulate the course of many viral infections. For example, HLA genes have
been shown to influence the progression of HIV infections and the severity of Hantaan virus
infections [40–42]. T1D-associated HLA genes have also been reported to influence the
immune response against EVs [43]. In the present study, the children who were heterozygous
for HLA-DQ2 and -DQ8 had fewer EV infections than the children who were homozygous for
these haplotypes. This is in line with other studies suggesting that homo- and heterozygosity in
the HLA alleles may modulate the course of a viral infection [44,45]. It is possible that hetero-
zygous individuals present a wider range of EV peptides to T-helper cells than homozygous
individuals. This could result in a faster clearance of the infection and a stronger inflammatory
response in heterozygous individuals compared to homozygous ones. On the other hand, we
did not find any sex differences in EV positivity even though boys are known to be more
prone to severe EV infections than girls. This may reflect the fact that the children of the cur-
rent study were asymptomatic.
In conclusion, the present study shows that EVs are frequent causes of infections in young
children with increased genetic risk for developing T1D. Viruses of the species Enterovirus A
were the most frequent EVs detected in all geographic areas in this study. In addition, there is
conspicuous variation between different geographic locations in the frequency of EV infec-
tions, and a particularly striking piece of evidence is showing the low frequency of EV infec-
tions in Finland. Such differences in the population dynamics of EVs may have important
consequences for the severity of EV diseases (and T1D) in these populations.
Supporting information
S1 Table. Distribution of HLA-DQ genotypes across the study centers. The numbers show
the number of children and the percentage within the center is also shown between brackets
N# (%).
(PDF)
S2 Table. Seasonal distribution of stool samples in different study centers according to the
month of sample collection (% of all samples).
(PDF)
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S3 Table. Oligonucleotides (primers and probes) employed in the EV RT-PCR.
(PDF)
S4 Table. Genotypes of EVs causing each individual infection episode in each study center
and in US and European (EU) centers combined.
(PDF)
S5 Table. The most frequently reported EVs in CDC reports representing the years covered
by the present study. The data has been extracted from the CDC reported Enterovirus and
Human Parechovirus Surveillance in the USA, covering the years 2006–2009 when the samples
were collected for the present study. The figures show the 16 most frequent EVs and parecho-
viruses in CDC reports, their rank and proportion (%) of all EV and parechovirus reports. The
rank and proportion of the same viruses in the present study is shown for comparison. CDC
reports were based on a total of 1395 typed EVs detected in different laboratories participating
in The National Enterovirus Surveillance System (NESS) [21,22].
(PDF)
S6 Table. Prevalence of different EV types by year of sample collection and age of the
child. The number of EV types detected in each year and by the age of the child. The age has
been divided into 6-month periods starting from birth.
(PDF)
S1 Fig. Defining enterovirus infection episodes. EV infection episodes were defined by the
presence of a positive PCR result, shown as the sample positivity in the figure, and the presence
of the same virus in consecutive samples. In this example the infection episode includes two
consecutive positive samples with the same virus identified by sequencing. The start of the epi-
sode (shown as S) was calculated as the mid-way between the time of the first positive sample
(sample B in the figure) and the preceding sample (sample A in the figure), indicated as (B-A)/
2. The end of the episode (shown as E) was defined as the mid-way point between the last of
the consecutively positive samples with the same virus (sample C) and the first sample negative
or positive for a different virus (sample D) indicated as (D-C)/2. The calculated mid-way point
at the beginning and the end of the episode could not be more than 15 days. In case a Ct-value
was not more than 25 for a positive sample at the beginning of an episode, the starting date
was set at 10 days prior to the time of the first positive sample (shown as S´). In case a Ct-value
was more than 35 for a positive sample at the end of the episode, the end date was set at 7 days
after the time of the last positive sample (shown E´).
(PDF)
S2 Fig. Distribution of Ct values of qPCR for EVs in stool samples. The Ct values are the
average of 3 independent experiments.
(PDF)
S3 Fig. Prevalence (%) of enteroviruses in children at different ages.
(PDF)
S4 Fig. EV positivity in children with different HLA-DQ genotypes and in boys and girls
(per sample and per child). Logistic regression was carried out to further analyze the differ-
ences between HLA groups along with the effect of the sex and the study center (see Fig 5).
(PDF)
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